Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PRAGYA B GUPTA

Allopathic & Osteopathic Physicians Pain Medicine Interventional Pain Medicine

NPI
1740243609
CMS profile
169630
Location
ESCONDIDO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$173.07

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $173.07 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Medtronic, Inc. $173.07 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PRAGYA B GUPTA

NPI 1740243609 · CMS profile ID 169630

Allopathic & Osteopathic Physicians / Pain Medicine / Interventional Pain Medicine

ESCONDIDO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740243609?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PRAGYA B GUPTA, NPI 1740243609, CMS profile ID 169630. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740243609?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). PRAGYA B GUPTA, NPI 1740243609, CMS profile ID 169630. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740243609?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
PRAGYA B GUPTA, NPI 1740243609, CMS profile ID 169630, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1740243609?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $173.07 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Medtronic, Inc. $173.0711/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933540885 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,197.89 23
PY2020 $521.91 5
PY2021 $28.94 1
PY2022 $173.07 1
PY2024 $323.46 18
PY2025 $122.68 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Recipient $110,396.02 4
PY2023 Principal investigator $345.00 1
PY2022 Recipient $225,815.70 4
PY2022 Principal investigator $11,408.50 2
PY2021 Recipient $27,383.28 3
PY2021 Principal investigator $470,706.93 67
PY2020 Recipient $400.00 2
PY2020 Principal investigator $25,458.20 11
PY2019 Recipient $19,721.65 13
PY2019 Principal investigator $135,598.30 34

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

47 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $8,827.93 12/31/2019 Non-covered Recipient Entity
OTRIMED CORPORATION
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670125617
Principal investigator 1 Allergan Inc. $591.50 12/31/2019 Non-covered Recipient Entity
OTRIMED CORPORATION
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670125631
Recipient US WorldMeds, LLC $137.70 12/31/2019 Covered Recipient Physician Lofexidine Clinical Adult Taper Study No dispute reported 06/30/2026 697502019
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $126.79 12/08/2019 Covered Recipient Physician Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD No dispute reported 06/30/2026 696049851
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $372.38 12/08/2019 Covered Recipient Physician Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD No dispute reported 06/30/2026 696049853
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $50.00 12/07/2019 Covered Recipient Physician Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD No dispute reported 06/30/2026 696049841
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $50.00 12/07/2019 Covered Recipient Physician Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD No dispute reported 06/30/2026 696049845
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $65.00 12/07/2019 Covered Recipient Physician Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD No dispute reported 06/30/2026 696049847
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $643.60 12/06/2019 Covered Recipient Physician Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD No dispute reported 06/30/2026 696049825
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $126.79 12/06/2019 Covered Recipient Physician Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD No dispute reported 06/30/2026 696049829
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $125.00 12/06/2019 Covered Recipient Physician Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD No dispute reported 06/30/2026 696049831
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $36.73 12/06/2019 Covered Recipient Physician Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD No dispute reported 06/30/2026 696049835
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $22.69 12/06/2019 Covered Recipient Physician Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD No dispute reported 06/30/2026 696049839
Recipient US WorldMeds, LLC $10,964.97 11/30/2019 Covered Recipient Physician Lofexidine Clinical Adult Taper Study No dispute reported 06/30/2026 697502017
Principal investigator 1 Medtronic, Inc. $7,407.00 11/26/2019 Non-covered Recipient Entity
Otrimed Corp
PSR-PSTM No dispute reported 06/30/2026 660556509
Principal investigator 1 Allergan Inc. $77.60 11/14/2019 Non-covered Recipient Entity
OTRIMED CORPORATION
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670097969
Principal investigator 1 Allergan Inc. $666.24 10/31/2019 Non-covered Recipient Entity
OTRIMED CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670093127
Principal investigator 1 Allergan Inc. $1,488.65 10/23/2019 Non-covered Recipient Entity
OTRIMED CORPORATION
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670090501
Recipient US WorldMeds, LLC $7,000.00 10/01/2019 Covered Recipient Physician Lofexidine Clinical Adult Taper Study No dispute reported 06/30/2026 697502015
Principal investigator 1 GRT US Holding, Inc. $1,694.70 09/25/2019 Non-covered Recipient Entity
OTRI-MED CORP
KF7013-02 No dispute reported 06/30/2026 692904661
Principal investigator 1 Allergan Inc. $2,164.10 09/20/2019 Non-covered Recipient Entity
OTRIMED CORPORATION
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670078825
Principal investigator 1 Allergan Inc. $2,410.15 09/20/2019 Non-covered Recipient Entity
OTRIMED CORPORATION
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670078955
Principal investigator 1 Medtronic, Inc. $474.00 08/26/2019 Non-covered Recipient Entity
Otrimed Corp
PSR-PSTM No dispute reported 06/30/2026 660556505
Principal investigator 1 PFIZER INC. $13,353.70 08/21/2019 Non-covered Recipient Entity
OTRIMED CORPORATION
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671659433
Principal investigator 1 Allergan Inc. $12,575.15 08/16/2019 Non-covered Recipient Entity
OTRIMED CORPORATION
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670067033
Principal investigator 1 Allergan Inc. $7,154.45 07/16/2019 Non-covered Recipient Entity
OTRIMED CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670057457
Principal investigator 1 Medtronic, Inc. $500.00 07/03/2019 Non-covered Recipient Entity
Otrimed Corp
PSR-PSTM No dispute reported 06/30/2026 660556499
Principal investigator 1 Allergan Inc. $6,500.00 07/01/2019 Non-covered Recipient Entity
OTRIMED CORPORATION
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670054249
Principal investigator 1 Allergan Inc. $500.00 07/01/2019 Non-covered Recipient Entity
OTRIMED CORPORATION
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670054253
Principal investigator 1 Allergan Inc. $660.00 06/25/2019 Non-covered Recipient Entity
OTRIMED CLINICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670053429
Principal investigator 1 PFIZER INC. $22,467.15 05/06/2019 Non-covered Recipient Entity
OtriMed Corporation
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVECONTROLLED MULTICENTER PARALLELGROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN No dispute reported 06/30/2026 671624793
Principal investigator 1 Allergan Inc. $289.68 04/30/2019 Non-covered Recipient Entity
OTRIMED CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670041810
Principal investigator 1 GRT US Holding, Inc. $3,782.25 04/25/2019 Non-covered Recipient Entity
OTRI-MED CORP
KF7013-02 No dispute reported 06/30/2026 692904659
Principal investigator 1 Allergan Inc. $3,188.20 04/23/2019 Non-covered Recipient Entity
OTRIMED CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670040011
Principal investigator 1 Allergan Inc. $4,075.50 02/28/2019 Non-covered Recipient Entity
OTRIMED CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670028053
Principal investigator 1 Allergan Inc. $4,628.40 02/19/2019 Non-covered Recipient Entity
OTRIMED CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670025667
Principal investigator 1 Medtronic, Inc. $727.00 02/15/2019 Non-covered Recipient Entity
Otrimed Corp
PSR-PSTM No dispute reported 06/30/2026 660556493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,022.82 02/12/2019 Non-covered Recipient Entity
OTRI-MED CORP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC LOW BACK PAIN AND OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 639750367
Principal investigator 1 GRT US Holding, Inc. $832.00 02/06/2019 Non-covered Recipient Entity
OTRI-MED CORP
KF7013-02 No dispute reported 06/30/2026 692904655
Principal investigator 1 GRT US Holding, Inc. $15,922.80 02/06/2019 Non-covered Recipient Entity
OTRI-MED CORP
KF7013-02 No dispute reported 06/30/2026 692904657
Principal investigator 1 Allergan Inc. $295.00 02/05/2019 Non-covered Recipient Entity
OTRIMED CLINICAL RESEARCH
EFFICACY AND SAFETY OF BIMATOPROST SUSTAINED-RELEASE SR IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION No dispute reported 06/30/2026 670022109
Principal investigator 1 Allergan Inc. $22.90 02/05/2019 Non-covered Recipient Entity
OTRIMED CLINICAL RESEARCH
EFFICACY AND SAFETY OF BIMATOPROST SUSTAINED-RELEASE SR IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION No dispute reported 06/30/2026 670022199
Principal investigator 1 Allergan Inc. $695.11 02/05/2019 Non-covered Recipient Entity
OTRIMED CLINICAL RESEARCH
EFFICACY AND SAFETY OF BIMATOPROST SUSTAINED-RELEASE SR IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION No dispute reported 06/30/2026 670022485
Principal investigator 1 Allergan Inc. $603.72 02/05/2019 Non-covered Recipient Entity
OTRIMED CLINICAL RESEARCH
EFFICACY AND SAFETY OF BIMATOPROST SUSTAINED-RELEASE SR IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION No dispute reported 06/30/2026 670022587
Principal investigator 1 Allergan Inc. $3,000.60 02/05/2019 Non-covered Recipient Entity
OTRIMED CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670022827
Principal investigator 1 Allergan Inc. $500.00 01/31/2019 Non-covered Recipient Entity
OTRIMED CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670021017
Principal investigator 1 Allergan Inc. $6,500.00 01/31/2019 Non-covered Recipient Entity
OTRIMED CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670021047